PD‑L1 expression in malignant melanomas of the skin and gastrointestinal tract

Akiyama,Michiko; Matsuda,Yoko; Arai,Tomio; Saeki,Hidehisa

doi:10.3892/ol.2020.11325

PD‑L1 expression in malignant melanomas of the skin and gastrointestinal tract

Authors:
- Michiko Akiyama
- Yoko Matsuda
- Tomio Arai
- Hidehisa Saeki
View Affiliations

Affiliations: Department of Dermatology, Nippon Medical School, Tokyo 113‑8603, Japan, Department of Pathology and Host‑Defense, Faculty of Medicine, Kagawa University, Miki‑cho, Kagawa 761‑0793, Japan, Department of Pathology, Tokyo Metropolitan Geriatric Hospital, Tokyo 173‑0015, Japan
Published online on: January 21, 2020 https://doi.org/10.3892/ol.2020.11325
Pages: 2481-2488

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastrointestinal melanoma (GM) is a rare but aggressive type of malignant melanoma arising in the gastrointestinal tract. An anti‑programmed cell death protein 1 (PD‑1) antibody markedly improves prognosis in patients with melanoma. However, little is known regarding the expression of immune‑oncology biomarkers in GM compared with skin melanoma (SM), especially in the Asian population. the present study examined clinicopathological characteristics, PD‑L1 and HLA expression, and immune‑oncology marker expression in 10 cases of GM and 31 cases of SM. Patients with GM exhibited significantly higher incidences of lymph node and distant metastases than patients with SM (P=0.0448 and P=0.0247, respectively). The infiltration of CD8+ lymphocytes was significantly higher in GM than in SM (P=0.0231). The infiltration of PD‑1+ lymphocytes was higher in GM than in SM, but the difference was not significant (P=0.0975). PD‑L1‑positive melanoma exhibited a higher proportion of BRAFV600E‑positive melanoma than PD‑L1‑negative melanoma (P=0.0317; 39.4 and 0%, respectively). PD‑L1‑positive melanoma exhibited significantly higher rates of CD8+ and FOXp3+ lymphocyte infiltration than PD‑L1‑negative melanoma (P=0.0221 and P=0.0463, respectively). By contrast, PD‑1+ lymphocytes did not differ between PD‑L1‑positive and ‑negative cases. Furthermore, HLA‑positive melanoma exhibited higher proportions of PD‑1 (P=0.0101; 53.7 and 15.4%) and CD8 than HLA‑negative melanoma (P=0.0818; 66.7 and 38.2%). These results provided useful information regarding tumor immunity in GM and SM and may contribute to the development of treatment strategies for GM.

View Figures

View References

1	Lee ML, Tomsu K and Von Eschen KB: Duration of survival for disseminated malignant melanoma: Results of a meta-analysis. Melanoma Res. 10:81–92. 2000.PubMed/NCBI
2	Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, et al: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 27:6199–6206. 2009. View Article : Google Scholar : PubMed/NCBI
3	Baderca F, Vincze D, Balica N and Solovan C: Mucosal melanomas in the elderly: Challenging cases and review of the literature. Clin Interv Aging. 9:929–937. 2014. View Article : Google Scholar : PubMed/NCBI
4	Chen H, Cai Y, Liu Y, He J, Hu Y, Xiao Q, Hu W and Ding K: Incidence, surgical treatment, and prognosis of anorectal melanoma from 1973 to 2011: A population-based SEER analysis. Medicine (Baltimore). 95:e27702016. View Article : Google Scholar : PubMed/NCBI
5	Arai T, Yanagisawa A, Kondo F, Aida J and Takubo K: Clinicopathologic characteristics of esophageal primary malignant melanoma. Esophagus. 13:17–24. 2016. View Article : Google Scholar
6	Cheung MC, Perez EA, Molina MA, Jin X, Gutierrez JC, Franceschi D, Livingstone AS and Koniaris LG: Defining the role of surgery for primary gastrointestinal tract melanoma. J Gastrointest Surg. 12:731–738. 2008. View Article : Google Scholar : PubMed/NCBI
7	Akiyama M, Matsuda Y, Arai T and Saeki H: Clinicopathological characteristics of malignant melanomas of the skin and gastrointestinal tract. Oncol Lett. 16:2675–2681. 2018.PubMed/NCBI
8	Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, et al: Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16:375–384. 2015. View Article : Google Scholar : PubMed/NCBI
9	Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, et al: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 192:1027–1034. 2000. View Article : Google Scholar : PubMed/NCBI
10	Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
11	Scheel AH, Dietel M, Heukamp LC, Jöhrens K, Kirchner T, Reu S, Rüschoff J, Schildhaus HU, Schirmacher P, Tiemann M, et al: Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol. 29:1165–1172. 2016. View Article : Google Scholar : PubMed/NCBI
12	Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, et al: Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 371:2189–2199. 2014. View Article : Google Scholar : PubMed/NCBI
13	Gibney GT, Weiner LM and Atkins MB: Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 17:e542–e551. 2016. View Article : Google Scholar : PubMed/NCBI
14	Hori S, Nomura T and Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science. 299:1057–1061. 2003. View Article : Google Scholar : PubMed/NCBI
15	Chen DS and Mellman I: Elements of cancer immunity and the cancer-immune set point. Nature. 541:321–330. 2017. View Article : Google Scholar : PubMed/NCBI
16	Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, Vilgelm AE, Feld E, Johnson AS, Greenplate AR, et al: Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun. 7:105822016. View Article : Google Scholar : PubMed/NCBI
17	Que Y, Xiao W, Guan YX, Liang Y, Yan SM, Chen HY, Li QQ, Xu BS, Zhou ZW and Zhang X: PD-L1 expression is associated with FOXP3⁺ regulatory T-cell infiltration of soft tissue sarcoma and poor patient prognosis. J Cancer. 8:2018–2025. 2017. View Article : Google Scholar : PubMed/NCBI
18	Pawelec G: Does patient age influence anti-cancer immunity? Semin Immunopathol. 41:125–131. 2019. View Article : Google Scholar : PubMed/NCBI
19	Kugel CH III, Douglass SM, Webster MR, Kaur A, Liu Q, Yin X, Weiss SA, Darvishian F, Al-Rohil RN, Ndoye A, et al: Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations. Clin Cancer Res. 24:5347–5356. 2018. View Article : Google Scholar : PubMed/NCBI
20	Espinosa E, Márquez-Rodas I, Soria A, Berrocal A, Manzano JL, Gonzalez-Cao M and Martin-Algarra S; Spanish Melanoma Group (GEM), : Predictive factors of response to immunotherapy-a review from the Spanish Melanoma Group (GEM). Ann Transl Med. 5:3892017. View Article : Google Scholar : PubMed/NCBI
21	Shang B and Liu Y, Jiang SJ and Liu Y: Prognostic value of tumor-infiltrating FoxP3⁺ regulatory T cells in cancers: A systematic review and meta-analysis. Sci Rep. 5:151792015. View Article : Google Scholar : PubMed/NCBI
22	Yun S, Park Y, Moon S, Ahn S, Lee K, Park HJ, Lee HS, Choe G and Lee KS: Clinicopathological and prognostic significance of programmed death ligand 1 expression in Korean melanoma patients. J Cancer. 10:3070–3078. 2019. View Article : Google Scholar : PubMed/NCBI
23	Frydenlund N, Leone D, Yang S, Hoang MP, Deng A, Hernandez-Perez M, Singh R, Biswas A, Yaar R and Mahalingam M: Tumoral PD-L1 expression in desmoplastic melanoma is associated with depth of invasion, tumor-infiltrating CD8 cytotoxic lymphocytes and the mixed cytomorphological variant. Mod Pathol. 30:357–369. 2017. View Article : Google Scholar : PubMed/NCBI
24	Kaunitz GJ, Cottrell TR, Lilo M, Muthappan V, Esandrio J, Berry S, Xu H, Ogurtsova A, Anders RA, Fischer AH, et al: Melanoma subtypes demonstrate distinct PD-L1 expression profiles. Lab Invest. 97:1063–1071. 2017. View Article : Google Scholar : PubMed/NCBI
25	Li Z, Dong P, Ren M, Song Y, Qian X, Yang Y, Li S, Zhang X and Liu F: PD-L1 expression is associated with tumor FOXP3(+) regulatory T-cell infiltration of breast cancer and poor prognosis of patient. J Cancer. 7:784–793. 2016. View Article : Google Scholar : PubMed/NCBI
26	Wang HY, Wu XY, Zhang X, Yang XH, Long YK, Feng YF and Wang F: Prevalence of NRAS mutation, PD-L1 expression and amplification, and overall survival analysis in 36 primary vaginal melanomas. Oncologist. Oct 2–2019.(Epub ahead of print). doi: 10.1634/theoncologist2019-0148. View Article : Google Scholar
27	Koelblinger P, Emberger M, Drach M, Cheng PF, Lang R, Levesque MP, Bauer JW and Dummer R: Increased tumour cell PD-L1 expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomas. J Eur Acad Dermatol Venereol. 33:667–675. 2019. View Article : Google Scholar : PubMed/NCBI
28	Thierauf J, Veit JA, Affolter A, Bergmann C, Grünow J, Laban S, Lennerz JK, Grünmüller L, Mauch C, Plinkert PK, et al: Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck. Melanoma Res. 25:503–509. 2015. View Article : Google Scholar : PubMed/NCBI